artificial intelligence (AI), which is has the potential to capture and assess Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs) to aid medical professionals in detecting and observing disease progression. Digital EMB and GMB tests are painless and time-saving as they may be performed in a short time in the waiting room or at home by the patient. At-home self-testing may help reduce appointment wait times and relieve strain on the health system, as well as benefit MS patients who live in remote regions and have difficulties in finding a neurologist.
Andrea Marazzi, Head of Country Pharma Organization, Novartis Pharmaceuticals, Canada Inc, spoke about the company’s mission and expressed hopes for future progress through the new collaboration. He said, “At Novartis, we are committed to helping solve Canada’s biggest health challenges, through innovative partnerships like the one we have with Innodem”. He added, “Canada has one of the highest rates of MS in the world. We joined forces with Innodem because we believe their eye movement tracking technology can help more rapidly identify disease progression and, in turn, improve management of MS. We are looking forward to seeing the results of the clinical trial and confirming the significance of this technology, granting more people living with MS and physicians access to this innovative software.”
MS is a chronic autoimmune disorder that affects the central nervous system. It occurs when the immune system targets particular areas of the brain and spinal cord, most notably the myelin, which is the protective coating that covers our neurons. MS affects around 90,000 individuals in Canada and is three times more prevalent in women compared to males.
Dr. Étienne de Villers-Sidani, Cognitive Neurologist and Main Founder and CEO of Innodem, expressed optimism over the partnership. He said, “Current eye tracking infrared technology is costly and not easily accessible, particularly in remote communities. By partnering with Novartis on this study we’re confident we can demonstrate the technology is efficient, accessible and scalable to people living with MS in Canada and across the world.”
